Roberto Latagliata, Paola Volpicelli, Massimo Breccia, Federico Vozella, Angela Romano, Chiara Montagna, Matteo Molica, Paola Finsinger, Ida Carmosino, Alessandra Serrao, Irene Zacheo, Michelina Santopietro, Adriano Salaroli, Giuliana Alimena
In patients with chronic myeloid leukemia (CML) responsive to imatinib, it is still unknown whether the long-lasting treatment could induce the appearance of a persistent/late chronic anemia. To highlight this issue, we revised 128 patients with CML (M/F 64/64, median age at diagnosis 56.9 years, interquartile range 43.0-69.3) treated at our Institution with 1st line imatinib for at least 36 months and in stable complete cytogenetic response. At the 36th month of imatinib, a chronic anemia (Hb < 12 g/dl for > 6 months) was present in 38/128 patients (29...
February 2015: American Journal of Hematology